MindBio Therapeutics Corp. is making significant strides in its Phase 2 clinical trials, as reported by CEO Justin Hanka. The company is currently conducting two trials using MB22001, its proprietary titratable form of LSD designed for take-home microdosing. The Phase 2a trial focuses on treating Major Depressive Disorder (MDD) in 20 patients, aiming for clinically significant improvements in depression rating scores as measured by the Montgomery Asberg Depression Rating Scale (MADRS). To date, nineteen out of twenty participants have begun their dosing regimen, with eight successfully completing their treatment.
Simultaneously, MindBio is conducting a Phase 2B trial targeting late-stage cancer patients experiencing existential distress, a condition characterized by a mix of depressive, anxiety, and distress symptoms. This trial involves 40 participants and is randomized and double-blind. The goal is to evaluate the effectiveness of MB22001 in alleviating these symptoms, with the hope of making the treatment accessible to end-of-life patients through special drug access schemes before regulatory approval.
MindBio's innovative approach to mental health treatment, particularly its focus on microdosing psychedelics, positions it as a leader in the field. The company's Phase 1 LSD-Microdosing clinical trial, completed in 2022, demonstrated no serious adverse events and reported significant increases in participants' feelings of happiness, social connectivity, wellness, creativity, and energy compared to a placebo group.
Justin Hanka emphasized the importance of these trials in advancing towards the commercialization of MB22001, aiming for a future where the treatment is widely available, safe, and effective for treating depression with minimal side effects. MindBio's commitment to developing novel treatments for mental health conditions through clinical trials and digital therapeutics underscores its dedication to improving mental health outcomes.
